CDT D0603: High-Throughput Antigen Testing for Public Health Pathogens

Headline: CDT code D0603: High-Throughput Antigen Testing for Public Health Pathogens

Lead: CDT code D0603 covers high-throughput antigen testing for public health–related pathogens, including SARS-CoV-2, billed on a per-day basis for laboratory services. The code standardizes reporting for large-scale antigen testing workflows used in surveillance and diagnostic settings.

What this code represents and national significance: CDT code D0603 captures laboratory-performed, high-throughput antigen testing for pathogens of public-health concern. As large-volume testing infrastructures remain a component of outbreak response and routine surveillance, a dedicated CDT code enables clearer billing, encounter tracking, and public-health reporting across laboratories.

Key payers covered: This analysis covers national private payers including Aetna; Blue Cross Blue Shield; Cigna Health; and UnitedHealthcare.

Overview of contents: Readers will find concise benchmarks and billing context for laboratory use of high-throughput antigen assays, comparisons to related infectious disease test codes, and clinical context for when antigen testing is applied. The publication highlights common service settings, coding relationships with nucleic acid and other antigen/antibody tests, and areas where input data is missing or limited.

Data limitations: Data not available in the input for service-line specifics and payer policy details; the publication notes where additional payer policy or reimbursement detail is needed.

Customize your policy alerts

Sign up for D0603 policy alerts

Get alerted when payer policies referencing D0603 are released or updated.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Billing Code Overview

CDT code D0603 describes antigen testing for a public health-related pathogen, including coronavirus (COVID-19), using a high throughput technique, per day. The service type is Laboratory, and the typical site of service is Laboratory (POS 81).

Data not available in the input.

National Reimbursement Benchmarks

National mean rates for CDT code D0603 show Medicare-equivalent discussion via BUCA (average commercial) at $19.90 compared with the major Medicare proxy represented in the payer mix: UnitedHealthcare and Blue Cross Blue Shield report substantially higher mean rates at $40.76 and $42.06 respectively, while Aetna and Cigna Health report lower means at $10.78 and $5.00. The BUCA average ($19.90) sits between the lower commercial payers and the higher large national payers.

Rate dispersion (P75 minus P25) varies across payers: Blue Cross Blue Shield has a wide dispersion (~~$42.33), UnitedHealthcare is also wide (~~$21.50), Aetna shows moderate dispersion (~~$17.00), BUCA is moderate (~~$16.25), and Cigna Health is the tightest with no dispersion ($0.00). The table and chart below present the full breakdown.

Explore openpayer tools

View all tools

CDT D0603: High-Throughput Antigen Testing for Public Health Pathogens

Headline: CDT code D0603: High-Throughput Antigen Testing for Public Health Pathogens

Key payers covered: This analysis covers national private payers including Aetna; Blue Cross Blue Shield; Cigna Health; and UnitedHealthcare.

Data limitations: Data not available in the input for service-line specifics and payer policy details; the publication notes where additional payer policy or reimbursement detail is needed.

Customize your policy alerts

Sign up for D0603 policy alerts

Get alerted when payer policies referencing D0603 are released or updated.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Billing Code Overview

Data not available in the input.

National Reimbursement Benchmarks

National Mean Rates for CDT code D0603 by Payer

Clinical & Coding Specifications

Clinical Context

A patient who is symptomatic for respiratory infection or has known exposure to COVID-19 presents to a clinical laboratory or specimen collection site. A laboratory technologist receives specimens and performs an antigen test for a public health-related pathogen, including SARS-CoV-2 (COVID-19), using a high-throughput technique. Results are processed on automated platforms and reported to the ordering clinician and public health authorities as required. Typical workflow steps: order entry by the clinician, specimen accessioning in the laboratory (POS 81), high-throughput antigen assay performed per manufacturer instructions, result verification by laboratory personnel, and transmission of results to the clinician and health department.

Related Codes

Code	Description
`87635`	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
`87426`	Infectious agent antigen detection by immunoassay technique, qualitative or semiquantitative; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
`86328`	Immunoassay for infectious agent antibody, qualitative or semiquantitative, single step method (e.g., reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
`86769`	Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])

87635: A molecular NAAT used for SARS-CoV-2 detection; often used as a confirmatory or primary diagnostic test when nucleic acid testing is indicated. It is a different methodology than high-throughput antigen testing.
87426: An antigen detection immunoassay for SARS-CoV-2; may be reported for antigen testing performed by immunoassay methods and can be an alternative to CDT code D0603 when the method and billing guidance align.
86328 and 86769: Serologic antibody tests for SARS-CoV-2; these detect host antibodies rather than viral antigen and are used at different points in the clinical workflow (post-infection or post-vaccination) rather than for acute antigen detection.
Common pairings/alternatives: D0603 may be used in workflows focused on high-throughput antigen testing; 87426 is a clinical alternative for antigen detection by immunoassay. 87635 is used when NAAT is performed instead of antigen testing. Serology codes 86328 and 86769 are not alternatives for acute antigen detection but are related laboratory services in COVID-19 testing pathways.

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Explore openpayer tools

View all tools

Clinical & Coding Specifications

Clinical Context

Related Codes

Code	Description
`87635`	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
`87426`	Infectious agent antigen detection by immunoassay technique, qualitative or semiquantitative; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
`86328`	Immunoassay for infectious agent antibody, qualitative or semiquantitative, single step method (e.g., reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
`86769`	Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])

87635: A molecular NAAT used for SARS-CoV-2 detection; often used as a confirmatory or primary diagnostic test when nucleic acid testing is indicated. It is a different methodology than high-throughput antigen testing.
87426: An antigen detection immunoassay for SARS-CoV-2; may be reported for antigen testing performed by immunoassay methods and can be an alternative to CDT code D0603 when the method and billing guidance align.
86328 and 86769: Serologic antibody tests for SARS-CoV-2; these detect host antibodies rather than viral antigen and are used at different points in the clinical workflow (post-infection or post-vaccination) rather than for acute antigen detection.
Common pairings/alternatives: D0603 may be used in workflows focused on high-throughput antigen testing; 87426 is a clinical alternative for antigen detection by immunoassay. 87635 is used when NAAT is performed instead of antigen testing. Serology codes 86328 and 86769 are not alternatives for acute antigen detection but are related laboratory services in COVID-19 testing pathways.

References

1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.

Published by

Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.